公开(公告)号：US11020396B2

公开(公告)日：2021-06-01

申请号：US16348073

申请日：2017-11-07

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: C07D403/14 ,  A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US09914730B2

公开(公告)日：2018-03-13

申请号：US14038915

申请日：2013-09-27

Applicant: Ignyta, Inc. ,  Cancer Research Technology Limited

Inventor： Henry J. Breslin ,  Bruce D. Dorsey ,  Benjamin J Dugan ,  Katherine M. Fowler ,  Robert L Hudkins ,  Eugen F. Mesaros ,  Nathaniel J. T. Monck ,  Emma L. Morris ,  Ikeoluwa Olowoye ,  Gregory R. Ott ,  Gregoire A. Pave ,  Jonathan R. Roffey ,  Christelle N. Soudy ,  Ming Tao ,  Craig A. Zificsak ,  Allison L. Zulli

IPC: A61K31/675 ,  C07D471/04 ,  C07D519/00 ,  C07D493/08 ,  C07D498/04 ,  C07F9/6584

CPC classification number: C07D471/04 ,  C07D493/08 ,  C07D498/04 ,  C07D519/00 ,  C07F9/6584

Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.

公开(公告)号：US11766434B2

公开(公告)日：2023-09-26

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US20220079942A1

公开(公告)日：2022-03-17

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US09896446B2

公开(公告)日：2018-02-20

申请号：US14975605

申请日：2015-12-18

Applicant: IGNYTA, INC. ,  Cancer Research Technology Limited

Inventor： Henry J. Breslin ,  Bruce D. Dorsey ,  Benjamin J. Dugan ,  Robert L. Hudkins ,  Eugen F. Mesaros ,  Gregory R. Ott ,  Craig A. Zificsak ,  Allison L. Zulli ,  Ming Tao ,  Katherine M. Fowler ,  Emma L. Morris ,  Gregoire A. Pave ,  Jonathan R. A. Roffey ,  Nathaniel J. T. Monck ,  Christelle N. Soudy ,  Ikeoluwa Olowoye

IPC: A61K31/407 ,  C07D471/04 ,  C07D519/00 ,  C07D493/08 ,  C07D498/04 ,  C07F9/6584

CPC classification number: C07D471/04 ,  C07D493/08 ,  C07D498/04 ,  C07D519/00 ,  C07F9/6584

Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

公开(公告)号：US20160102094A1

公开(公告)日：2016-04-14

申请号：US14975605

申请日：2015-12-18

Applicant: Cancer Research Technology Limited ,  IGNYTA, INC.

Inventor： Henry J. Breslin ,  Bruce D. Dorsey ,  Benjamin J. Dugan ,  Robert L. Hudkins ,  Eugen F. Mesaros ,  Gregory R. Ott ,  Craig A. Zificsak ,  Allison L. Zulli ,  Ming Tao ,  Katherine M. Fowler ,  Emma L. Morris ,  Gregoire A. Pave ,  Jonathan R.A. Roffey ,  Nathaneil J.T. Monck ,  Christelle N. Soudy ,  Ikeoluwa Olowoye

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D493/08 ,  C07D498/04 ,  C07D519/00 ,  C07F9/6584

Abstract: The present application provides a compound of formula (1) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

Abstract translation: 本申请提供式（1）化合物或其盐，其中R 7，R 8，R 9，G和X如本文所定义。 本申请进一步描述了包含该组合物的组合物。 式（I）化合物及其盐具有PKC抑制活性，可用于治疗增殖性疾病。

公开(公告)号：US20150274720A1

公开(公告)日：2015-10-01

申请号：US14668022

申请日：2015-03-25

Applicant: Ignyta, Inc. ,  Cancer Research Technology Limited

Inventor： Bruce D. Dorsey ,  Benjamin J. Dugan ,  Katherine M. Fowler ,  Robert L. Hudkins ,  Eugen F. Mesaros ,  Nathaniel JT Monck ,  Emma L. Morris ,  Ikeoluwa Olowoye ,  Gregory R. Ott ,  Gregoire A. Pave ,  Jonathan R.A. Roffey ,  Christelle N. Soudy ,  Craig A. Zificsak ,  Allison L. Zulli

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07D519/00

Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

Abstract translation: 本申请提供式（I）化合物和/或其盐，其中R 1，G和X如本文所定义。 式（I）化合物和/或其盐具有PKC抑制活性，可用于治疗增殖性疾病。 还提供了包含式（I）化合物和/或其盐的组合物。

公开(公告)号：US10919896B2

公开(公告)日：2021-02-16

申请号：US16335379

申请日：2017-09-22

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Anne Cochi ,  Benjamin J. Dugan ,  Chukuemeka Tennyson Ekwuru ,  Fred Elustondo ,  Katherine M. Fowler ,  Frederic Georges Marie Leroux ,  Nathaniel J. T. Monck ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Gurwinder Sidhu ,  Neil Tremayne

IPC: C07D401/14 ,  C07D487/02 ,  A61P35/00

Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US20190336502A1

公开(公告)日：2019-11-07

申请号：US16348073

申请日：2017-11-07

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  C07D417/14 ,  A61K31/551 ,  A61K31/437 ,  C07D471/04 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US10414763B2

公开(公告)日：2019-09-17

申请号：US14668022

申请日：2015-03-25

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Bruce D. Dorsey ,  Benjamin J. Dugan ,  Katherine M. Fowler ,  Robert L. Hudkins ,  Eugen F. Mesaros ,  Nathaniel J T Monck ,  Emma L. Morris ,  Ikeoluwa Olowoye ,  Gregory R. Ott ,  Gregoire A. Pave ,  Jonathan R. A. Roffey ,  Christelle N. Soudy ,  Craig A. Zificsak ,  Allison L. Zulli

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61K31/437

Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.